Various agents targeting TLR2 or TLR5, such as CBLB612 (a synthetic lipopeptide agonist of TLR5), ISA-201B (a peptide agonist of TLR2), and OPN-305 (a monoclonal antibody inhibiting TLR2), also known as tomaralimab, have also been tested in phase I and II trials in patients with several cancer types, but the results have been published to date (NCT02778763; NCT03669718; NCT02363491). This evidence concerns the gene TLR2 and cancer.